Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Cell Death and Disease

Volumn 4, Issue 9, 2013, Pages

  Matthews, G M ^a,b   Lefebure, M ^a,b   Doyle, M A ^a   Shortt, J ^a,b   Ellul, J ^a   Chesi, M ^c   Banks, K M ^a,b   Vidacs, E ^a,b   Faulkner, D ^a   Atadja, P ^d   Bergsagel, P L ^c   Johnstone, R W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MAYO CLINIC   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

DNA methylation; Extrinsic apoptosis; Histone deacetylase inhibitors; Intrinsic apoptosis; Multiple myeloma

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AZACITIDINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PANOBINOSTAT; PARAPROTEIN; PROTEIN BCL 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ROMIDEPSIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SURVIVAL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; BIPHENYL COMPOUNDS; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE MYELOMA; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84884996251     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.306     Document Type: Article

References (54)

1. Kyle RA, Buadi F, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) 2011; 25: 578-586
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873
3. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-180
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9
5. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351
6. Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 2008; 93: 860-869
7. Utecht KN, Kolesar J. Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 2008; 65: 1221-1231
8. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011; 67: 175-195
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784
10. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94
11. Fantin V, Richon VM. Mechansims of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007; 13: 7237-7242
12. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009; 28: 3097-3110
13. Rasheed W, Bishton M, Johnstone R, Prince M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008; 8: 413-432
14. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11: 542-552
15. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Lett 2009; 280: 233-241
16. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789
17. Martin BP, Frew AJ, Bots M, Fox S, Long F, Takeda K et al. Antitumor activities and on-Target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int J Cancer 2011; 128: 2735-2747
18. Buchwald M, Kramer OH, Heinzel T. HDACi-Targets beyond chromatin. Cancer Lett 2009; 280: 160-167
19. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157-164
20. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Molecular Cell 2010; 37: 299-310
21. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388
22. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000
23. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005; 115: 2648-2655
24. Letai A. BCL-2: Found bound and drugged! Trends Mol Med 2005; 11: 442-444
25. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681
26. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13(Part 1): 621-629
27. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798
28. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27: 6207-6215
29. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125-133
30. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008; 105: 11317-11322
31. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks K-M, Coomans C et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009; 113: 1982-1991
32. Wiegmans AP, Alsop A, Bots M, Cluse LA, Williams SP, Banks K-M et al. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 2011; 71: 3603-3615
33. Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2010; 148: 702-713
34. NojimaM,Maruyama R, Yasui H, Suzuki H,Maruyama Y, Tarasawa I et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 2009; 15: 4356-4364
35. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376-385
36. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035
37. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114: 380-393
38. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071-8076
39. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838
40. Wu D, Smyth GK. Camera: A competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 2012; 40: E133
41. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 2009; 69: 5307-5311
42. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-397
43. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062
44. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2004; 12: 228-237
45. Guo F, Sigua C, Tao J, Bali P, George P, Li Y et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64: 2580-2589
46. Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010; 5: E10376
47. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 2008; 180: 1545-1555
48. Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313: 2378-2388
49. Brennan SK, Matsui W. Cancer stem cells: Controversies in multiple myeloma. J Mol Med (Berl) 2009; 87: 1079-1085
50. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I et al. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 2009; 15: 1998-2009
51. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413
52. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. Bcl-2 inhibitors: Small molecules with a big impact on cancer therapy. Cell Death Differ 2008; 16: 360-367
53. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
54. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446